Regeneron (REGN) PT Raised to $659 at Brean Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron (REGN) PT Raised to $664 at Leerink Partners; Reacceleration in Eylea
August 4, 2015 3:45 PM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on Regeneron Pharma (NASDAQ: REGN) to $664.00 (from $630.00) following solid Q2 results this morning. The analyst noted reacceleration in Eylea, particularly due to demand in diabetic macular edema (DME).
Schwartz... More
Regeneron Pharma's (REGN) Price Target Boosted to $665 at RBC
August 4, 2015 3:19 PM EDTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $665.00 (from $570.00). Analyst Adnan Butt said the set up looks "ideal" for near and long-term outperformance.
"Eylea beat and guidance raise were substantial, driving nearterm gains. Mid-term... More
Regeneron Pharma's (REGN) Price Target Raised to $720 at Deutsche Bank
August 4, 2015 1:19 PM EDTDeutsche Bank maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $720.00 (from $650.00). The change follows Q2 results. Analyst Robyn Karnauskas noted Eylea is still growing at 50% year-over-year.
"Just when street was thinking about potential stabilization of Eylea share, 2Q US numbers surprised... More
Regeneron (REGN) Tops Q2 EPS by 12c
August 4, 2015 6:34 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $2.89, $0.12 better than the analyst estimate of $2.77. Revenue for the quarter came in at $999 million versus the consensus estimate of $887.81 million.
Pipeline Progress
Regeneron has fifteen fully human monoclonal antibodies generated using the Company's VelocImmune® technology in clinical development, including five in collaboration with Sanofi(5). In addition to Praluent,... More
